What are Vascepa's FDA-approved uses?
Vascepa (icosapent ethyl) is approved by the FDA to reduce cardiovascular risk in specific adult patients. The primary indication, approved in December 2020 based on the REDUCE-IT trial, covers adults with elevated triglycerides (≥150 mg/dL) who are already on statin therapy and have either established cardiovascular disease or diabetes plus additional risk factors (like age ≥55 with one more factor such as hypertension or smoking). This approval targets prevention of major events like heart attacks, strokes, and cardiovascular death.[1]
A narrower prior indication from 2012 allows use to reduce triglyceride levels (≥500 mg/dL) as an add-on to diet in adults with severe hypertriglyceridemia, when statins alone aren't enough.[1]
How does this differ from earlier approvals?
The 2012 approval focused solely on lowering high triglycerides to prevent pancreatitis, without cardiovascular outcome data. The 2020 expansion, under the "Expanded Cardiovascular Outcomes Benefit" category, shifted it to a preventive therapy for heart events, supported by trial data showing a 25% relative risk reduction in the primary endpoint.[1][2]
What about off-label or unapproved uses?
FDA approval limits Vascepa to these two indications. Uses like standalone cholesterol lowering or primary prevention without the specified criteria lack approval and aren't supported by labeling.[1]
Who makes Vascepa and when did approvals happen?
Amarin Pharma manufactures Vascepa. Key FDA dates: July 26, 2012 (triglycerides), and December 23, 2020 (CV risk reduction).[1]
[1]: FDA Vascepa Label
[2]: NEJM REDUCE-IT Study